Michael Howell - 18 Jun 2024 Form 4 Insider Report for Zura Bio Ltd (ZURA)

Reporting relationship: Chief Scientific Officer and Head of Translational Science
Issuer ticker: ZURA
Reported as of: 18 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2024, 18:11:56 UTC
Prior SEC filing: 08 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Howell

Key filing fact

Michael Howell filed Form 4 for Zura Bio Ltd (ZURA) on 21 Jun 2024.

Key facts

This page summarizes Michael Howell's Form 4 filing for Zura Bio Ltd (ZURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2024, 18:11.

Change

Previous filing in this sequence was filed on 08 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZURA transaction Derivative

Employee Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +295,000
Change %
Price: $0.000000
Shares after: 295,000
Date: 18 Jun 2024
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 295,000
Exercise price: $3.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One fourth (1/4th) of the shares subject to the option award shall vest on June 18, 2025, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

SEC remarks

Chief Scientific Officer and Head of Translational Science